Studies of cell channels lead to therapeutic antibodies in clinical trials Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Dec. 12, 2022) — Jean X. Jiang, PhD, whose pioneering research has given rise to potential bone cancer and brain injury therapeutics currently under evaluation in clinical trials, will be inducted as a Fellow of the National […]

The AHEAD clinical trial will assess whether the new Alzheimer’s drug, lecanemab, can delay the onset of dementia in persons who are at high risk of developing the disease. Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Dec. 1, 2022) — The Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, part of The University of Texas […]

Elacestrant may improve care of metastatic ER+/HER2- tumors Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Nov. 30, 2022) — Phase III results of EMERALD, a clinical trial evaluating a novel oral drug therapy for metastatic ER-positive/HER2-negative (ER+/HER2-) breast cancer, will be presented Thursday, Dec. 8, at the San Antonio Breast Cancer Symposium (SABCS). Virginia Kaklamani, MD, […]

Metformin, SGLT-2 inhibitors and insulin resistance among career highlights Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Nov. 29, 2022) — Ralph A. DeFronzo, MD, professor of medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and deputy director of University Health’s Texas Diabetes Institute, will receive one of […]